Last reviewed · How we verify
NCT03734640
Optimal Post Tpa-Iv Monitoring in Ischemic Stroke
NA trial testing Low-intensity monitoring strategy in Acute Ischemic Stroke Patients Receiving Reperfusion Therapy in 4,922 participants. Completed in 23 January 2025.
1 December 2024
Quick facts
| Lead sponsor | Craig Anderson |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 4,922 |
| Start date | 28 April 2021 |
| Primary completion | 1 December 2024 |
| Estimated completion | 23 January 2025 |
| Sites | 54 locations across Malaysia, Chile, United Kingdom, Mexico, Australia, China, United States |
Drugs / interventions tested
- Low-intensity monitoring strategy
- Guideline recommended standard monitoring
Conditions studied
- Acute Ischemic Stroke Patients Receiving Reperfusion Therapy — all drugs for Acute Ischemic Stroke Patients Receiving Reperfusion Therapy →
Sponsor
Craig Anderson
Who can join
18 and older, any sex, with Acute Ischemic Stroke Patients Receiving Reperfusion Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
OPTIMISTmain is an investigator-initiated and conducted, international, multicentre, stepped wedge cluster randomized controlled trial comparing the effects of different intensities of nursing care monitoring for patients with acute ischemic stroke of mild severity and without critical care needs after IV-tPA.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.
Anderson CS, Summers D, Ouyang M, Sui Y, et al · · 2025 · cited 7× · PMID 40412428 · DOI 10.1016/s0140-6736(25)00549-5 -
Low-Intensity Monitoring After Stroke Thrombolysis During the COVID-19 Pandemic.
Faigle R, Johnson B, Summers D, Khatri P, et al · · 2020 · cited 7× · PMID 32514708 · DOI 10.1007/s12028-020-00998-0 -
Glyceryl trinitrate for treating hyperacute stroke: the Efficacy of Nitric Oxide in Stroke-2 (ENOS-2) feasibility randomised controlled trial
Woodhouse LJ, Mhlanga I, Buck A, Gray L, et al · · 2025 · cited 1× · DOI 10.21203/rs.3.rs-7494203/v1 -
Statistical Analysis Plan for the Optimal Post rTpa-Iv Monitoring in Ischemic Stroke Trial (OPTIMIST)
Billot L, Bompoint S, Ouyang M, Xu L, et al · · 2024 · cited 1× · DOI 10.1101/2024.12.17.24319094 -
Low-Intensity Monitoring for Mild-to-Moderate Acute Ischemic Stroke Is Cost Saving: Economic Evaluation for OPTIMISTmain.
Xu L, Ouyang M, Atkins ER, Summers D, et al · · 2026 · PMID 41608808 · DOI 10.1161/strokeaha.125.053506
Verify or expand the search:
- PubMed search for NCT03734640
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03734640 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Craig Anderson
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03734640.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing